Clinical trial
A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout and Moderate Renal Impairment
NCT02128490 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout and Moderate Renal Impairment
- Lead sponsor
- Takeda
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- October 31, 2015
- Enrollment
- 189 (actual)
- Sites
- 89
Conditions
As the registry lists them; a condition with its own page is linked.
gout, moderate renal impairment